The ABCA7 transporter, brain lipids and Alzheimer's disease

Clinical Lipidology

Volumn 8, Issue 1, 2013, Pages 97-108

  Soscia, Stephanie J ^a   Fitzgerald, Michael L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ABCA1; ABCA7; Alzheimer's disease; amyloid ; ApoE; ApoJ; brain; cholesterol homeostasis; genome wide association study; lipid

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A7; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; CHOLESTEROL; CHOLESTEROL ESTER; CLUSTERIN; DIACYLGLYCEROL; FARNESYL DIPHOSPHATE; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GERANYLGERANYL PYROPHOSPHATE; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PHOSPHOLIPID; PLASMALOGEN; SPHINGOLIPID; UNCLASSIFIED DRUG;

ABCA7 GENE; ALZHEIMER DISEASE; AMYLOID PLAQUE; APP GENE; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; GENE; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LIPID ANALYSIS; LIPID BRAIN LEVEL; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEMBRANE TRANSPORT; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873425235     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.91     Document Type: Review

References (138)

1. Chan RB, Oliveira TG, Cortes EP et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287(4), 2678-2688 (2012
2. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: Cholesterol and beyond. Nat. Rev. Neurosci. 12(5), 284-296 (2011
3. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 8(6), 429-431 (1995
4. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120(4), 545-555 (2005
5. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120(3), 885-890 (1984
6. Goldgaber D, Lerman MI, Mcbride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235(4791), 877-880 (1987
7. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-Surface receptor. Nature 325(6106), 733-736 (1987
8. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc. Natl Acad. Sci. USA 84(12), 4190-4194 (1987
9. Tanzi RE, Gusella JF, Watkins PC et al. Amyloid beta protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235(4791), 880-884 (1987
10. Schellenberg GD, Bird TD, Wijsman EM et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258(5082), 668-671 (1992
11. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375(6534), 754-760 (1995
12. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269(5226), 973-977 (1995
13. Rogaev EI, Sherrington R, Rogaeva EA et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376(6543), 775-778 (1995
14. Pericak-Vance MA, Bebout JL, Gaskell PC, JR et al. Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48(6), 1034-1050 (1991
15. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: High-Avidity binding to beta-Amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90(5), 1977-1981 (1993
16. Schmechel DE, Saunders AM, Strittmatter WJ et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90(20), 9649-9653 (1993
17. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101-112 (2007
18. Mclean CA, Cherny RA, Fraser FW et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46(6), 860-866 (1999
19. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-Translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta 1406(3), 291-298 (1998
20. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-Term depression by disrupting neuronal glutamate uptake. Neuron 62(6), 788-801 (2009
21. Cheng IH, Scearce-Levie K, Legleiter J et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282(33), 23818-23828 (2007
22. Hollingworth P, Harold D, Sims R et al. Common variants at ABCA7, MS4A6A/ MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43(5), 429-435 (2011
23. Eisenstein M. Genetics: Finding risk factors. Nature 475(7355), S20-S22 (2011
24. Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron 52(1), 15-31 (2006
25. Grosgen S, Grimm MO, Friess P, Hartmann T. Role of amyloid beta in lipid homeostasis. Biochim. Biophys. Acta 1801(8), 966-974 (2010
26. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-Amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95(11), 6460-6464 (1998
27. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-Amyloid production. Biochim. Biophys. Acta 1801(8), 860-867 (2010
28. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-Amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160(1), 113-123 (2003
29. Vetrivel KS, Meckler X, Chen Y et al. Alzheimer disease Abeta production in the absence of S-palmitoylation-Dependent targeting of BACE1 to lipid rafts. J. Biol. Chem. 284(6), 3793-3803 (2009
30. Hattori C, Asai M, Onishi H et al. BACE1 interacts with lipid raft proteins. J. Neurosci. Res. 84(4), 912-917 (2006
31. Urano Y, Hayashi I, Isoo N et al. Association of active gamma-Secretase complex with lipid rafts. J. Lipid Res. 46(5), 904-912 (2005
32. Marquer C, Devauges V, Cossec JC et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 25(4), 1295-1305 (2011
33. Schneider A, Rajendran L, Honsho M et al. Flotillin-Dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28(11), 2874-2882 (2008
34. Martin V, Fabelo N, Santpere G et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. 19(2), 489-502 (2010
35. Kokjohn TA, Van Vickle GD, Maarouf CL et al. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim. Biophys. Acta 1812(11), 1508-1514 (2011
36. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9(2), 139-150 (2008
37. Posse De Chaves E, Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 584(9), 1748-1759 (2010
38. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 31(3), 398-408 (2010
39. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 1801(8), 878-886 (2010
40. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-Site amyloid precursor protein-Cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 278(22), 19777-19783 (2003
41. Grimm MO, Grimm HS, Patzold AJ et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7(11), 1118-1123 (2005
42. Hooff GP, Wood WG, Muller WE, Eckert GP. Isoprenoids, small GTPases and Alzheimer's disease. Biochim. Biophys. Acta 1801(8), 896-905 (2010
43. Cole SL, Vassar R. Isoprenoids and Alzheimer's disease: A complex relationship. Neurobiol. Dis. 22(2), 209-222 (2006
44. Oliveira TG, Di Paolo G. Phospholipase D in brain function and Alzheimer's disease. Biochim. Biophys. Acta 1801(8), 799-805 (2010
45. Sanchez-Mejia RO, Newman JW, Toh S et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 11(11), 1311-1318 (2008
46. Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease Y a review. J. Lipid Res. 49(6), 1157-1175 (2008
47. Matsuzaki K, Kato K, Yanagisawa K. Abeta polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta 1801(8), 868-877 (2010
48. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G. Human brain gangliosides in development, aging and disease. Int. J. Dev. Biol. 35(3), 289-295 (1991
49. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77(4), 1168-1180 (2001
50. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 443(7112), 651-657 (2006
51. Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-Diseased brains. J. Neurochem. 48(4), 1018-1021 (1987
52. Landman N, Jeong SY, Shin SY et al. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl Acad. Sci. USA 103(51), 19524-19529 (2006
53. Berman DE, Dall'Armi C, Voronov SV et al. Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nat. Neurosci. 11(5), 547-554 (2008
54. Shui G, Guan XL, Low CP et al. Toward one step analysis of cellular lipidomes using liquid chromatography coupled with mass spectrometry: Application to Saccharomyces cerevisiae and Schizosaccharomyces pombe lipidomics. Mol. Biosyst. 6(6), 1008-1017 (2010
55. Foley P. Lipids in Alzheimer's disease: A century-old story. Biochim. Biophys. Acta 1801(8), 750-753 (2010
56. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: The lipid connection. J. Neurochem. 103(SUPPL1), 159-170 (2007
57. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12(2), 105-112 (2001
58. Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol. 16(2), 193-212 (2005
59. Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol. 22, 129-157 (2006
60. Hirsch-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important for Alzheimer disease? Mol. Cell. Biochem. 326(1-2), 121-129 (2009
61. Civeira F, Pocovi M, Cenarro A et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis 127(2), 273-282 (1996
62. Breslow JL, Zannis VI, Sangiacomo TR, Third JL, Tracy T, Glueck CJ. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23(8), 1224-1235 (1982
63. Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, Marz W. Molecular basis of type III hyperlipoproteinemia in Germany. Hum. Mutat. 11(6), 417-423 (1998
64. Jiang Q, Lee CY, Mandrekar S et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 58(5), 681-693 (2008
65. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76(4), 1501-1513 (1985
66. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262(29), 14352-14360 (1987
67. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10(3), 241-252 (2011
68. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63(3), 287-303 (2009
69. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123), 921-923 (1993
70. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43(8), 1467-1472 (1993
71. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400 (1996
72. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342(8873), 697-699 (1993
73. West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci. Lett. 175(1-2), 46-48 (1994
74. Chiang GC, Insel PS, Tosun D et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology 75(22), 1976-1981 (2010
75. Bandaru VV, Troncoso J, Wheeler D et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol. Aging 30(4), 591-599 (2009
76. Bales KR, Verina T, Cummins DJ et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 96(26), 15233-15238 (1999
77. Holtzman DM, Bales KR, Wu S et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103(6), R15-R21 (1999
78. Filippini N, Macintosh BJ, Hough MG et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl Acad. Sci. USA 106(17), 7209-7214 (2009
79. Reiman EM, Chen K, Liu X et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106(16), 6820-6825 (2009
80. Hashimoto T, Serrano-Pozo A, Hori Y et al. Apolipoprotein E, especially apolipoprotein e4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 32(43), 15181-15192 (2012
81. Castellano JM, Kim J, Stewart FR et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3(89), 89ra57 (2011
82. Deane R, Sagare A, Hamm K et al. apoE isoform-Specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118(12), 4002-4013 (2008
83. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 16(6), 287-294 (2010
84. Reiman EM, Chen K, Langbaum JB et al. Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage 49(1), 169-176 (2010
85. Caselli RJ, Dueck AC, Osborne D et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 361(3), 255-263 (2009
86. Miyata M, Smith JD. Apolipoprotein E allele-Specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-Amyloid peptides. Nat. Genet. 14(1), 55-61 (1996
87. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41(10), 1088-1093 (2009
88. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41(10), 1094-1099 (2009
89. May PC, Johnson SA, Poirier J, Lampert-Etchells M, Finch CE. Altered gene expression in Alzheimer's disease brain tissue. Can. J. Neurol. Sci. 16(SUPPL4), 473-476 (1989
90. Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic. Res. 40(12), 1324-1334 (2006
91. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25(3), 95-98 (2000
92. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-Competent state. Biochemistry 39(51), 15953-15960 (2000
93. Kumita JR, Poon S, Caddy GL et al. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369(1), 157-167 (2007
94. Yerbury JJ, Poon S, Meehan S et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21(10), 2312-2322 (2007
95. Shibata M, Yamada S, Kumar SR et al. Clearance of Alzheimer's amyloid-Ss(1-40) peptide from brain by LDL receptor-related protein-1 at the bloodYbrain barrier. J. Clin. Invest. 106(12), 1489-1499 (2000
96. Bell RD, Sagare AP, Friedman AE et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27(5), 909-918 (2007
97. Demattos RB, Cirrito JR, Parsadanian M et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41(2), 193-202 (2004
98. De Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: Structure and tissue distribution. Biochemistry 29(22), 5380-5389 (1990
99. Jenne DE, Tschopp J. Clusterin: The intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17(4), 154-159 (1992
100. De Silva HV, Stuart WD, Duvic CR et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265(22), 13240-13247 (1990
101. Mccarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008
102. Moskvina V, Schmidt KM. On multiple-Testing correction in genome-wide association studies. Genet. Epidemiol. 32(6), 567-573 (2008
103. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet. Epidemiol. 32(3), 227-234 (2008
104. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 32(4), 381-385 (2008
105. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-Analyses. Nat. Rev. Neurosci. 9(10), 768-778 (2008
106. Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathol. Appl. Neurobiol. 37(4), 353-357 (2011
107. Bertram L, Mcqueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-Analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat. Genet. 39(1), 17-23 (2007
108. Kaminski WE, Orso E, Diederich W, Klucken J, Drobnik W, Schmitz G. Identification of a novel human sterol-Sensitive ATP-binding cassette transporter (ABCA7). Biochem. Biophys. Res. Commun. 273(2), 532-538 (2000
109. Fitzgerald ML, Mendez AJ, Moore KJ, Andersson LP, Panjeton HA, Freeman MW. ATP-binding cassette transporter A1 contains an NH2-Terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J. Biol. Chem. 276(18), 15137-15145 (2001
110. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 275(42), 33053-33058 (2000
111. Bungert S, Molday LL, Molday RS. Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters: Identification of N-linked glycosylation sites. J. Biol. Chem. 276(26), 23539-23546 (2001
112. Beharry S, Zhong M, Molday RS. N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-Specific ABC transporter ABCA4 (ABCR). J. Biol. Chem. 279(52), 53972-53979 (2004
113. Yanagi T, Akiyama M, Nishihara H et al. Self-improvement of keratinocyte differentiation defects during skin maturation in ABCA12-Deficient harlequin ichthyosis model mice. Am. J. Pathol. 177(1), 106-118 (2010
114. Kim WS, Fitzgerald ML, Kang K et al. ABCA7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 280(5), 3989-3995 (2005
115. Wang N, Lan D, Gerbod-Giannone M et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J. Biol. Chem. 278(44), 42906-42912 (2003
116. Linsel-Nitschke P, Jehle AW, Shan J et al. Potential role of ABCA7 in cellular lipid efflux to apoA-I. J. Lipid Res. 46(1), 86-92 (2005
117. Abe-Dohmae S, Ikeda Y, Matsuo M et al. Human ABCA7 supports apolipoprotein-Mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J. Biol. Chem. 279(1), 604-611 (2004
118. Jehle AW, Gardai SJ, Li S et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J. Cell Biol. 174(4), 547-556 (2006
119. Tanaka N, Abe-Dohmae S, Iwamoto N, Fitzgerald ML, Yokoyama S. Helical apolipoproteins of high-Density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J. Lipid Res. 51(9), 2591-2599 (2010
120. Iwamoto N, Abe-Dohmae S, Sato R, Yokoyama S. ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis. J. Lipid Res. 47(9), 1915-1927 (2006
121. Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J. Atheroscler. Thromb. 18(4), 274-281 (2011
122. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10(1), 19-45 (1995
123. Chan SL, Kim WS, Kwok JB et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem. 106(2), 793-804 (2008
124. Logge W, Cheng D, Chesworth R et al. Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. PLoS one 7(9), e45959 (2012
125. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS one 7(11), e50976 (2012
126. Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-Density lipoprotein deficiency. Nat. Genet. 22(4), 336-345 (1999
127. Karasinska JM, Rinninger F, Lutjohann D et al. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J. Neurosci. 29(11), 3579-3589 (2009
128. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: The Whitehall II study. Arterioscler. Thromb. Vasc. Biol. 28(8), 1556-1562 (2008
129. Chu LW, Li Y, Li Z et al. A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(8), 1007-1013 (2007
130. Rodriguez-Rodriguez E, Mateo I, Llorca J et al. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(7), 964-968 (2007
131. Wahrle SE, Jiang H, Parsadanian M et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280(52), 43236-43242 (2005
132. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280(52), 43224-43235 (2005
133. Hirsch-Reinshagen V, Maia LF, Burgess BL et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280(52), 43243-43256 (2005
134. Wahrle SE, Jiang H, Parsadanian M et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118(2), 671-682 (2008
135. Burns MP, Vardanian L, Pajoohesh-Ganji A et al. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 98(3), 792-800 (2006
136. Cramer PE, Cirrito JR, Wesson DW et al. ApoE-Directed therapeutics rapidly clear beta-Amyloid and reverse deficits in AD mouse models. Science 335(6075), 1503-1506 (2012
137. Dietschy JM, Turley SD. Thematic review series: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45(8), 1375-1397 (2004
138. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. BloodYbrain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology 68(21), 1809-1814 (2007